Single-step dose activation
A dose is ready when the cover is opened fully. The counter automatically keeps track of remaining doses.
No priming required
The ARNUITY ELLIPTA requires no priming and is breath actuated - no hand-breath coordination required.
At the conclusion of a 4-week, open-label, placebo study in adult patients with asthma (N=250),
96% demonstrated correct use* and rated the ELLIPTA inhaler "easy to use."
Inhalers did not contain active treatment.
*Study Details: correct use was evaluated using instructions derived from the prescribing information for products delivered in the ELLIPTA inhaler. At enrollment, patients were allowed up to 3 attempts to demonstrate correct use (with training between attempts 1 and 2, and 2 and 3 if necessary), and all patients were able to demonstrate correct use. On Day 28, patients were evaluated for correct use in a single attempt without additional instruction. 98% demonstrated correct use.